ADALIMUMAB

Brand name:

• Yuflyma®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque psoriasis Moderate to severe hidradenitis suppurativa

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (Category 3)

Comment:

--

Submission sponsor:

Celltrion Healthcare Australia Pty Ltd

Other PBAC consideration:

--

Submission received for:

July 2022 PBAC meeting

Opportunity for consumer comment:

Open 30/03/2022 and close 25/05/2022 (see PBS Website)

PBAC meeting:

Held on 06/07/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

15/08/2022

Lodgement of required documentation:

26/08/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 01/09/2022

Status:

Finalised

Government processes:

Commenced on 15/11/2022

Medicine listed on the PBS:

01/03/2023 (see PBS schedule)

---